Stocktoria
Theravance Biopharma, Inc. TBPH
Theravance Biopharma, Inc. (TBPH) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $107.5M at a 98.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.783 |
| Retained earnings / assets | -1.77 |
| EBIT / assets | -0.007 |
| Equity / liabilities | 1.571 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TBPH | Theravance Biopharma, Inc. | 6/9 | 0.96 | 8.6 | +66.9% |
| ZVRA | ZEVRA THERAPEUTICS, INC. | 5/9 | -0.84 | 9 | +350.9% |
| ZYME | Zymeworks Inc. | 5/9 | -3.24 | — | +38.9% |
| URGN | UroGen Pharma Ltd. | 1/9 | -15.59 | — | +21.4% |
| GYRE | GYRE THERAPEUTICS, INC. | 3/9 | 4.52 | 71 | +10.2% |
| ASRT | Assertio Holdings, Inc. | 2/9 | -6.37 | — | -5% |
| SIGA | SIGA TECHNOLOGIES INC | 5/9 | 16.02 | 12.1 | -31.8% |
About Theravance Biopharma, Inc.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
FAQ
Is TBPH financially healthy?
Theravance Biopharma, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TBPH pay a dividend?
No, Theravance Biopharma, Inc. does not currently pay a dividend.
How profitable is TBPH?
In FY2025, Theravance Biopharma, Inc. had a net margin of 98.5% and a return on equity of 35.7%.
What is TBPH's P/E ratio?
Theravance Biopharma, Inc.'s trailing price-to-earnings (P/E) ratio is about 8.6×, based on its latest annual earnings.
What is the analyst price target for TBPH?
The average Wall-Street price target for Theravance Biopharma, Inc. is $16.50, about 2.5% below the recent price, from 4 analysts.
Is TBPH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Theravance Biopharma, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 8.6×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.